Novel approaches to the treatment of type 2 diabetes

Journal of Pharmacy Practice

Volumn 22, Issue 3, 2009, Pages 320-332

  St Onge, Erin L ^a   Miller, Shannon A ^b   Taylor, James R ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Family Health Center East   (United States)

Author keywords

DPP IV inhibitor; GLP 1; Incretin; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; BIPHASIC INSULIN; DENAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; GRC 8200; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PLACEBO; PSN 9301; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ACUTE PANCREATITIS; ADD ON THERAPY; B LYMPHOCYTE; BLOATING; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LACTIC ACIDOSIS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 66249095620     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008326578     Document Type: Review

References (45)

1. Available at: www.cdc.gov/diabetes/pubs/pdf/ndfs-2005.pdf. Accessed November 2007.
2. Turner RC, Cull CA, Frighi V., Holman R. for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999 ; 281: 2005-2012. (Pubitemid 29254858)
3. Saydah SH, Fradkin J., Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004 ; 291: 335-342. (Pubitemid 38101606)
4. Koro CE, Bowlin SJ, Bourgeois N., Fedder DO Glycemia control from 1998 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004 ; 27: 17-20. (Pubitemid 38196703)
5. Triplitt C., Wright A., Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. 2006 ; 26: 360-374. (Pubitemid 43334676)
6. Miller SA, St Onge EL Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006 ; 40: 1336-1343. (Pubitemid 44204964)
7. DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999 ; 131: 281-303.
8. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006 ; 29: 1963-1972.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 ; 356: 2457-2471. (Pubitemid 46919772)
10. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007 ; 147: 386-399.
11. Lacy C., Armstrong L., Goldman M., Lance L. Drug Information Handbook. 13 th ed. Cleveland, OH: Lexicomp Inc ; 2005.
12. Nielsen LL, Young AA, Parkes DG Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004 ; 117: 77-88. (Pubitemid 38045329)
13. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/exenatideHCP. htm. Accessed Octtober 22, 2007.
14. Buse JB, Henry RR, Han J. et al, and the Exenatide-113 Clinical Study Group. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 2628-2635. (Pubitemid 39441462)
15. DeFronzo RA, Ratner RE, Han J., Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 ; 28: 1092-1100. (Pubitemid 40616618)
16. Kendall DM, Riddle MC, Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005 ; 28: 1083-1091. (Pubitemid 40616617)
17. Zinman B., Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med. 2007 ; 146: 477-485.
18. Heine RJ, VanGaal LF, Johns D. and the GWAA Study Group. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005 ; 143: 559-569. (Pubitemid 41476552)
19. Nauck MA, Duran S., Kim D., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007 ; 50: 259-267.
20. Ratner RE, Maggs D., Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006 ; 8: 419-428. (Pubitemid 44349234)
21. Kim D., MacConell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007 ; 30: 1487-1493. (Pubitemid 46871159)
22. Drucker DJ, Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 ; 368: 1696-1705. (Pubitemid 46048557)
23. Scott R., Wu M., Sanchez M., Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007 ; 61: 171-180. (Pubitemid 46269371)
24. Aschner P., Kipnes MS, Lunceford JK, Sanchez M., Mickel C., Williams-Herman DE, and the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 ; 29: 2632-2637.
25. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman DE, Khatami H., and the Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006 ; 49: 2564-2571.
26. Goldstein B., Feinglos M., Lunceford J., Johnson J., Williams-Herman DE, and the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 ; 30: 1979-1987. (Pubitemid 47219404)
27. Brazg R., Xu L., Man C., Cobelli C., Thomas K., Stein PP Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and ?2-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007 ; 9: 186-193. (Pubitemid 46206562)
28. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G., and the Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006 ; 29: 2638-2643.
29. Nauck M., Meininger G., Sheng D., Terranella L., Stein PP, and the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007 ; 9: 194-205. (Pubitemid 46206563)
30. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P., and the Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diab Obes Metab. 2007 ; 9: 733-745. (Pubitemid 47261855)
31. Rosenstock J., Brazg R., Andryuk P., Lu K., Stein P., and the Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006 ; 28: 1556-1568.
32. Henness S., Keam S. Vildagliptin. Drugs. 2006 ; 66: 1989-2001.
33. Campbell, R Keith. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2007 ; 41: 51-60. (Pubitemid 46145957)
34. Lauster CD, McKaveney TP, Muench SV Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm. 2007 ; 64: 1265-1273. (Pubitemid 47216194)
35. Baker DE Current FDA-related drug information. Hosp Pharm. 2007 ; 42: 457-463. (Pubitemid 34251725)
36. Ahren B., Landin-Olsson M., Jansson PA, Svensson M., Holmes D., Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrin Metab. 2004 ; 89: 2078-2084. (Pubitemid 38619835)
37. Ristic S., Byiers S., Foley J., Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005 ; 7: 692-698. (Pubitemid 41601073)
38. Pratley Re, Jauffret-Kamel S., Galbreath E., Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006 ; 38: 423-428. (Pubitemid 44047965)
39. Dejager S., Razac S., Foley JE, Schweizer A. Vildagliptin in drug-na?»?»ve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007 ; 39: 218-233. (Pubitemid 46580622)
40. Pi-Sunyer FX, Schweizer A., Mills D., Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-na?»?»ve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007 ; 76: 132-138. (Pubitemid 46240373)
41. Rosenstock J., Baron MA, Dejager S., Mills D., Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007 ; 30: 217-223. (Pubitemid 46198322)
42. Ahren B., Gomis R., Standl E., Mills D., Schweizer A. Twelve and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 2874-2880. (Pubitemid 39565052)
43. Bosi E., Camisasca R., Collober C., Rochotte E., Garber AJ Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007 ; 30: 890-895. (Pubitemid 46556583)
44. Bolli G., Dotta F., Rochotte E., Cohen SE Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diab Obes Metab. 2008 ; 10: 82-90. (Pubitemid 350302434)
45. Fonseca V., Dejager S., Albrecht D., Shirt L., Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM) [Abstract 467-P]. Paper presented at: The American Diabetes Association 66th Annual Scientific Sessions; June 9-13, 2006 ; Washington, DC.